Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of oral SHR2285 for prevention of venous thromboembolism after elective total knee arthroplasty
CTR20212948Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of shr2285 in venous thromboembolism (VTE), sponsored by Hengrui Therapeutics. Started Mar 2022; status: terminated.
02
Drugs
shr2285
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20212948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212948.